News

Cablivi is claimed to be the first therapeutic specifically developed to treat aTTP, a rare blood-clotting disorder. The approval was based on data from the phase II Titan

The planned 90,000ft² quality control facility, which will have 12 production suites, is expected to enable Wasdell to provide quality control (QC) import testing for pharmaceutical products. To

The initial recommended prophylactic regimen for Jivi is twice weekly with the ability to dose every five days and further individually adjust to less or more frequent dosing

The franchise includes the global rights to ONCASPAR and ex-US and ex-Taiwan rights to ONIVYDE, as well as Oncology pipeline assets.  David Lee, who was previously the head

AstraZeneca, along with its global biologics research and development arm MedImmune, has reported the top-line results from the Tulip 1 phase III trial for anifrolumab in adult patients

The FDA in its complete response letter issued to the company conveyed that the new drug application (NDA) for dasotraline could not be approved in its current form.

The original contract in Alzheimer’s disease was announced on 5 July 2017 and this change order reflects an extension of the contract term from September 2020 to May

The Phase 2 study (B5161002), did not meet its primary efficacy endpoint, which was to demonstrate a difference in the mean change from baseline in 4 Stair Climb

Delstrigo is a once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg). Pifeltro (doravirine, 100mg) is a new non-nucleoside reverse transcriptase